Keith W. Marshall - 15 Feb 2023 Form 4 Insider Report for Prometheus Biosciences, Inc.

Role: Chief Financial Officer
Signature: /s/ Timothy K. Andrews, attorney-in-fact for Keith W. Marshall
Issuer symbol: N/A
Transactions as of: 15 Feb 2023
Net transactions value: -$578,400
Form type: 4
Filing time: 17 Feb 2023, 20:34:06 UTC
Previous filing: 19 Jan 2023
Next filing: 08 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXDX	Common Stock	Options Exercise	$18,500	+5,000	+51%	$3.70^*	14,811	15 Feb 2023	Direct	F1
transaction	RXDX	Common Stock	Sale	$596,900	-5,000	-34%	$119.38	9,811	15 Feb 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXDX	Stock Option (Right to Buy)	Options Exercise	$0	-5,000	-4.2%	$0.000000	113,040	15 Feb 2023	Common Stock	5,000	$3.70	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3	25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.